Millions are Taking a Drug that Falls Short of its Promise to Lower Risk of Heart Attack
Posted
Dr. John A. Osborne (via MedCity News)
While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a benefit of fenofibrates over and above statins in further reducing heart-related events.
The post Millions are Taking a Drug that Falls Short of its Promise to Lower Risk of Heart Attack appeared first on MedCity News.
